Fluvoxamine maleate is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program, using the contact information at the bottom of this page.
Selective Serotonin Reuptake Inhibitors (SSRIs) Information FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies[ARCHIVED]
Antidepressant Use in Children, Adolescents, and Adults[ARCHIVED]
Information for Healthcare Professionals: Fluvoxamine - Selective Serotonin Reuptake Inhibitors (SSRIs)[ARCHIVED]
Public Health Advisory: Treatment Challenges of Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in Newborns[ARCHIVED]
Information for Healthcare Professionals: Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), 5-Hydroxytryptamine Receptor Agonists (Triptans)[ARCHIVED]
Public Health Advisory - Combined Use of 5-Hydroxytryptamine Receptor Agonists (Triptans), Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) May Result in Life-threatening Serotonin Syndrome[ARCHIVED]
Fluvoxamine Maleate Historical Information[ARCHIVED]
FDA Alert issued 7/2005